Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme: a population-based analysis.

Autor: Walker GV, Li J, Mahajan A, McAleer MF, de Groot JF, Azeem SS, Brown PD, Walker, Gary V, Li, Jing, Mahajan, Anita, McAleer, Mary Frances, de Groot, John F, Azeem, Syed S, Brown, Paul D

Publikováno v: Cancer (0008543X); Sep2012, Vol. 118 Issue 18, p4538-4544, 7p

ACR-ARS Practice Parameter for Communication: Radiation Oncology.

Autor: Saeed H; Lynn Cancer Institute Boca Raton, Baptist Health, Boca Raton., Wallner PE; Genesis Care, Moorestown, NJ., Bates JE; Winship Cancer Institute, Atlanta, GA., Chundury A; Loyola University Medical Center., Freedman LM; Loyola University Medical Center., Mitin T; Oregon Health and Science University, Portland, OR., Walker GV; Banner MD Anderson Cancer Center, Gilbert, AZ., Small W Jr; Department of Radiation Oncology, Maguire Center, Maywood.; Banner MD Anderson Cancer Center, Gilbert, AZ., Schechter NR; South Florida Proton Therapy Institute, Delray Beach, FL.; Rakuten-Medical, San Diego, CA.

Publikováno v: American journal of clinical oncology [Am J Clin Oncol] 2024 May 01; Vol. 47 (5), pp. 210-216. Date of Electronic Publication: 2023 Dec 25.

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.

Autor: Negrao MV; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Papadimitrakopoulou VA; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Price AC; Department of Radiology, Banner MD Anderson Cancer Center, Gilbert, Arizona., Tam AL; Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Furqan M; Department of Internal Medicine, Carver College of Medicine, University of Iowa Health Care, Iowa City, Iowa., Laroia ST; Department of Radiology, Division of Vascular and Interventional Radiology, Carver College of Medicine, University of Iowa Health Care, Iowa City, Iowa., Massarelli E; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California., Pacheco J; Department of Medicine-Medical Oncology, University of Colorado, Aurora, Colorado., Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tsao AS; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Walker GV; Department of Radiology, Banner MD Anderson Cancer Center, Gilbert, Arizona., Vora L; Department of Diagnostic Radiology, City of Hope, Duarte, California., Mauro D; Checkmate Pharmaceuticals, Cambridge, Massachusetts., Kelley H; Checkmate Pharmaceuticals, Cambridge, Massachusetts., Wooldridge JE; Checkmate Pharmaceuticals, Cambridge, Massachusetts., Krieg AM; Checkmate Pharmaceuticals, Cambridge, Massachusetts., Niu J; Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2022 Oct 26; Vol. 4 (3), pp. 100423. Date of Electronic Publication: 2022 Oct 26 (Print Publication: 2023).

PSA: Declining utilization of prostate brachytherapy.

Autor: Andring L; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX. Electronic address: lmandring@mdanderson.org., Yoder A; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX., Pezzi T; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX., Tang C; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX., Kumar R; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX; Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ., Mahmood U; Department of Radiation Oncology, Torrance Memorial Medical Center, Torrance, CA., Walker GV; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX; Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ.

Publikováno v: Brachytherapy [Brachytherapy] 2022 Jan-Feb; Vol. 21 (1), pp. 6-11. Date of Electronic Publication: 2021 Aug 20.

An in-silico quality assurance study of contouring target volumes in thoracic tumors within a cooperative group setting.

Autor: Elhalawani H; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA., Elgohari B; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA., Lin TA; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.; Baylor College of Medicine, TX 77030, USA., Mohamed ASR; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.; Department of Clinical Oncology and Nuclear Medicine, Alexandria University, Alexandria, Egypt., Fitzgerald TJ; Imaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Worcester, Massachusetts, USA., Laurie F; Imaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Worcester, Massachusetts, USA., Ulin K; Imaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Worcester, Massachusetts, USA., Kalpathy-Cramer J; Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Massachusetts, USA., Guerrero T; Department of Radiation Oncology, Beaumont Health System, Royal Oak, MI, USA., Holliday EB; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA., Russo G; Department of Radiation Oncology, Boston Medical Center, Massachusetts, USA., Patel A; Department of Radiation Oncology, University of Texas Health Sciences Center at San Antonio, TX, USA., Jones W; Department of Radiation Oncology, University of Texas Health Sciences Center at San Antonio, TX, USA., Walker GV; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.; Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona, USA., Awan M; Department of Radiation Oncology, Case Western Reserve University, OH, USA., Choi M; Department of Radiation Oncology, Northwestern University, IL, USA., Dagan R; University of Florida Health Proton Therapy Institute, FL, USA., Mahmoud O; Department of Radiation Oncology, University of Miami, FL, USA., Shapiro A; Department of Radiation Oncology, Upstate Cancer Center, SUNY Upstate Medical University, NY, USA., Kong FS; Department of Radiation Oncology, University Hospitals Cleveland Medical Center, OH, USA., Gomez D; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA., Zeng J; Department of Radiation Oncology, University of Washington Medical Center, WA, USA., Decker R; Department of Therapeutic Radiology, Yale University School of Medicine, Connecticut, USA., Spoelstra FOB; Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., Gaspar LE; Department of Radiation Oncology, Vanderbilt University, TN, USA., Kachnic LA; Department of Radiation Oncology, Vanderbilt University Medical Center, Tennessee, USA., Thomas CR Jr; Department of Radiation Medicine, Oregon Health & Science University, Oregon, USA., Okunieff P; SWOG, Department of Radiation Oncology, University of Florida College of Medicine, Florida, USA., Fuller CD; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.

Publikováno v: Clinical and translational radiation oncology [Clin Transl Radiat Oncol] 2019 Jan 06; Vol. 15, pp. 83-92. Date of Electronic Publication: 2019 Jan 06 (Print Publication: 2019).